IP Library Granted Patent US 7,323,195
Granted Patent B2
US 7,323,195 · App. 10/919,969 · Granted Jan 29, 2008

Enteric formulations of proanthocyanidin polymer antidiarrheal compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,323,195
App. No.
10/919,969
Granted
Jan 29, 2008
Kind
B2
Abstract

Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.

Claims (12)

1. A pharmaceutical composition comprising an aqueous soluble isolated proanthocyanidin polymer composition from a Croton spp. or from a Calophyllum spp., formulated with an enteric coating to protect the proanthocyanidin polymer composition from the stomach environment; and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising an with aqueous soluble isolated proanthocyanidin polymer composition from a Croton species or a Calophyllum species, formulated to protect the proanthocyanidin polymer composition from the stomach environment in a controlled release preparation for oral administration, and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1 , in which the Croton spp. is Croton lechleri.

4. The pharmaceutical composition of claim 2 , in which the Croton spp. is Croton lechleri.

5. The pharmaceutical composition of claim 1 , in which the enteric coating is comprised of a methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.

6. The pharmaceutical composition of claim 1 , which is formulated as a compressed tablet.

7. The pharmaceutical composition of claim 1 , which is formulated as an enteric-coated capsule.

8. The pharmaceutical composition of claim 1 , formulated as a capsule, in which the capsule contains beads, each bead comprising a core of the proanthocyanidin polymer composition, and the beads further comprising a layer of enteric coating.

9. The pharmaceutical composition of claim 1 , which further comprises a lubricant.

10. The pharmaceutical composition of claim 2 , which further comprises a lubricant.

11. The pharmaceutical composition of claim 9 , in which the lubricant is magnesium stearate.

12. The pharmaceutical composition of claim 1 , in which the isolated proanthocyanidin polymer composition is formulated as enteric coated granules or powder.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2018
From: HERCULES CAPITAL, INC.
To: JAGUAR HEALTH, INC.
Reel/Frame 045496/0039 →
SECURITY INTEREST Recorded Nov 22, 2017
From: NAPO PHARMACEUTICALS, INC.
To: KINGDON CAPITAL MANAGEMENT, L.L.C.
Reel/Frame 044497/0954 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2017
From: NANTUCKET INVESTMENTS LIMITED
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 043380/0655 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 12, 2016
From: JAGUAR ANIMAL HEALTH, INC.
To: HERCULES TECHNOLGY GROWTH CAPITAL, INC., AS AGENT
Reel/Frame 037809/0161 →
SECURITY AGREEMENT Recorded Mar 7, 2012
From: NAPO PHARMACEUTICALS, INC.
To: NANTUCKET INVESTMENTS LIMITED
Reel/Frame 027830/0255 →